Recovery
Apraglutide
Also called FE 203799
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Quick start
Apraglutide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 2.5–5 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~6.3 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Apraglutide describe 2.5–5 mg per administration. Descriptive only, not a recommendation.
Around 30 hours in reported work; supports weekly spacing.
Dosing schedule
How Apraglutide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Reported doseA long-acting GLP-2 analog dosed weekly in the STARS phase-3 program. | 2.5–5 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 0.99× single dose
- Time to steady state
- 6.3days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Apraglutide STARS phase-3 programWeekly subcutaneous apraglutide (FE 203799) at 2.5–5 mg assessed for intestinal absorption in short-bowel syndrome.